Prescription Drugs: Cost Effectiveness
Lords · Question HL15136 · Tabled 3 Mar 2026 · Department of Health and Social Care · Official record
Answered 11 Mar 2026
Question
Asked by Baroness Shawcross-Wolfson
To ask His Majesty's Government what assessment they have made of the number of National Institute for Health and Care Excellence appraisals which are paused pending increases in the cost per quality-adjusted life year threshold in April.
Answer
Answered by Baroness Merron, 11 Mar 2026
There are currently two appraisals paused, at the request of the company, until the National Institute for Health and Care Excellence (NICE) has the power to apply the new cost-effectiveness threshold:Vorasidenib for treating astrocytoma or oligodendrogli...